Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat
Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat
$131.00
Pharma companies faced a “patent cliff” a decade ago with generic competition threatening to slash sales of certain blockbusters. The new threat is biosimilars. Scrip shows how some mature cancer and autoimmune biologics are still the major drivers of revenues, and how biosimilars are gaining on them.
Publisher: Scrip
- Description
As biologics have grown to dominate the market in the past decade, the threat to established pharmaceuticals is no longer generics, it’s biosimilars. First look at the evolution of pharma’s blockbuster drugs. Then see the top drugs by molecule type, therapy area and how biologics have grown in the last decade, to get a clearer picture of how the golden age of the first wave of monoclonal antibodies is waning. This Scrip infographic also shows the new US and UK biosimilars on the horizon with a clear scan of the launch dates and companies and current drugs in their cross hairs.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
What Does It Take To Launch And Lead An Oncology Biotech Today? 
Sign up to the